Champignon Brands Inc (CSE:SHRM) (OTCQB:SHRMF) (FRA:496) reported that its management and governance is undergoing “comprehensive change at the top“ that will extend to the company's practices.
Champignon Brands said it is doing so in order to emphasize transparency, full and accurate public reporting plus operational readiness to “meet the accelerating, pandemic-drive demand for its clinical services.”
These changes include:
- The company’s previously announced appointment of a new board chair, CEO, and new vice-chair
- Recruiting a new CFO, chief general counsel, and senior vice president of investor and public communications
- Its intention to expand its board with additional outside directors to be drawn from business and science
- A re-designed website to facilitate proper access to current information by investors and the wider public
READ: Champignon Brands is making a scientific case for psychedelic medicine
The current board for Champignon Brands consists of Dr Roger McIntyre, chair and CEO; Bill Wilkerson, vice-chair; Matt Fish, president and secretary; and Jerry Habuda. Former director Gareth Birdsall has resigned effective November 23.
Champignon Brands is emerging as a leader in the burgeoning field of psychedelic medicine by pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders.
As one of the first psychedelic companies to go public, its network of ketamine clinics complements its sharp focus on research and development.
Its strategic approach establishes a differentiated platform with operating treatment clinics in the US and Canada that also facilitate research and development of a wide range of therapeutic and medical applications of psilocybin, the psychoactive ingredient in mushrooms.
Contact Sean at [email protected]
